Janssen Biotech is paying refunds for overcharges on certain 340B drugs purchased in the third quarter of 2020.

Janssen Issuing Refunds for 340B Overcharges

September 8, 2023 Tom Mirga, Editor at Large Views

Drug manufacturer Janssen Biotech recently determined that it owes or may owe refunds to some 340B covered entities. The refunds [...]

Please Login or Become a Paid Subscriber to View this Content

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!